Industry Projects - View By Region
Stay up to date with the project updates by clicking on the map or choosing a region from the list below.Projects Region Map
Projects Region Listing
Latest Projects - View By Region
Simbrinza (brinzolamide/brimonidine tartrate) for the Reduction of Elevated Intraocular Pressure
Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of...
Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of...
Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women
Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency....
Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency....
Zytiga (abiraterone acetate) - Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research....
Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research....
Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome
Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome....
Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome....
Elelyso (Taliglucerase Alfa) for Treating Gaucher Disease
Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and...
Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and...
Gattex (Teduglutide) for Treatment of Short Bowel Syndrome (SBS)
Gattex (teduglutide) is a subcutaneous injection indicated for the treatment of adult patients with short bowel syndrome (SBS). The drug was developed and manufactured by NPS Pharmaceuticals...
Gattex (teduglutide) is a subcutaneous injection indicated for the treatment of adult patients with short bowel syndrome (SBS). The drug was developed and manufactured by NPS Pharmaceuticals...
Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC)
Stivarga (regorafenib), developed by Bayer HealthCare, is an oral multikinase inhibitor indicated for the treatment of metastatic colorectal cancer (mCRC). The US Food and Drug Administration...
Stivarga (regorafenib), developed by Bayer HealthCare, is an oral multikinase inhibitor indicated for the treatment of metastatic colorectal cancer (mCRC). The US Food and Drug Administration...
BG-12 (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS)
BG-12 (Dimethyl Fumarate) is an investigational drug indicated for treating relapsing-remitting multiple sclerosis (RRMS). The drug was developed by Biogen Idec. The drug received...
BG-12 (Dimethyl Fumarate) is an investigational drug indicated for treating relapsing-remitting multiple sclerosis (RRMS). The drug was developed by Biogen Idec. The drug received...
Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia
Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for...
Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for...
Iclusig (ponatinib) for the Treatment of Chronic Myeloid Leukaemia
Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered,...
Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered,...
Twitter
Facebook